Camille Verebi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Camille Verebi has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
France Leturcq
Service de Médecine Génomique des Maladies de Système Et d’Organe, Hôpital Cochin, APHP. Centre Université de Paris Cité, Paris, France
9 shared publications- Thierry Bienvenu
Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Equipe Gorwood/Ramoz Paris France
6 shared publications Juliette Nectoux
Service de Médecine Génomique des Maladies de Système Et d’Organe, Hôpital Cochin, APHP. Centre Université de Paris Cité, Paris, France
5 shared publications- Juliette Nectoux
Service de Médecine Génomique Des Maladies de Système et D'organe Hôpital Cochin, AP.HP.CUP Paris France
5 shared publications Thierry Bienvenu
Service de Médecine Génomique des maladies de système et d'organe Fédération de Génétique et de Médecine Génomique AP‐HP.Centre—Université de Paris Hôpital Cochin Paris France
5 shared publicationsLucie Orhant
Service de Médecine Génomique des maladies de système et d'organe, APHP.Centre - Université Paris Cité, Hôpital Cochin, Paris, France
3 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Extending the ATP9A ‐Related Phenotypic Spectrum: Indication of Schizophrenia Susceptibility
ATP9A, which belongs to the P4‐ATPase family of proteins, is involved in the efficient transport of vesicles from the Golgi apparatus to the plasma membrane, as well as the release of extracellular vesicles from human cells. In 2021, a loss‐of‐function variant of this gene was identified as being associated with a recessive neurodevelopmental disorder characterized by severe intellectual disability, motor delay, speech impairment, impaired fine motor skills, and behavioral anomalies, such as attention deficit hyperactivity disorder and aggressive behavior. Furthermore, in 2025, a de novo missense variant in the same gene was identified as being associated with a dominant neurodevelopmental disorder exhibiting a very similar phenotype. In this study, we identified three novel de novo variants in the ATP9A gene in two unrelated patients diagnosed with schizophrenia or schizoaffective disorder by performing trio short‐read whole‐genome sequencing (WGS). One individual presenting with severe psychosis was found to carry a de novo synonymous variant, c.2113C>T, p.(Leu705=), in the ATP9A gene. All software predicted that this variant would alter the 5′ splice site of intron 19. An intron minigene assay showed that it disrupts normal gene splicing. The second individual, who had refractory schizophrenia, was found to carry two variants in the ATP9A gene: a de novo nonsense variant c.1740C>G, p.(Tyr580*), and a large de novo deletion including exons 18 and 19 of the ATP9A gene (GRCh38:g.51517885_51628972del). We demonstrated the presence of these two rare variants in cis using long‐range PCR. Our findings suggest that individuals with ATP9A gene variants may exhibit severe psychiatric disorders, regardless of the inheritance pattern. ATP9A plays a role in neuronal development and may therefore be involved in the development of psychiatric disorders. This warrants specific attention to heterozygous individuals. Our results reinforce the data obtained in the largest exome meta‐analysis conducted by the SCHEMA consortium. That study showed that protein‐truncating and pathogenic missense variants in ATP9A were significantly associated with schizophrenia ( p = 0.000372; odds Ratio = 5.48).
- 18 September 2026
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Open AccessExtending the ATP9A ‐Related Phenotypic Spectrum: Indication of Schizophrenia Susceptibility
ATP9A, which belongs to the P4‐ATPase family of proteins, is involved in the efficient transport of vesicles from the Golgi apparatus to the plasma membrane, as well as the release of extracellular vesicles from human cells. In 2021, a loss‐of‐function variant of this gene was identified as being associated with a recessive neurodevelopmental disorder characterized by severe intellectual disability, motor delay, speech impairment, impaired fine motor skills, and behavioral anomalies, such as attention deficit hyperactivity disorder and aggressive behavior. Furthermore, in 2025, a de novo missense variant in the same gene was identified as being associated with a dominant neurodevelopmental disorder exhibiting a very similar phenotype. In this study, we identified three novel de novo variants in the ATP9A gene in two unrelated patients diagnosed with schizophrenia or schizoaffective disorder by performing trio short‐read whole‐genome sequencing (WGS). One individual presenting with severe psychosis was found to carry a de novo synonymous variant, c.2113C>T, p.(Leu705=), in the ATP9A gene. All software predicted that this variant would alter the 5′ splice site of intron 19. An intron minigene assay showed that it disrupts normal gene splicing. The second individual, who had refractory schizophrenia, was found to carry two variants in the ATP9A gene: a de novo nonsense variant c.1740C>G, p.(Tyr580*), and a large de novo deletion including exons 18 and 19 of the ATP9A gene (GRCh38:g.51517885_51628972del). We demonstrated the presence of these two rare variants in cis using long‐range PCR. Our findings suggest that individuals with ATP9A gene variants may exhibit severe psychiatric disorders, regardless of the inheritance pattern. ATP9A plays a role in neuronal development and may therefore be involved in the development of psychiatric disorders. This warrants specific attention to heterozygous individuals. Our results reinforce the data obtained in the largest exome meta‐analysis conducted by the SCHEMA consortium. That study showed that protein‐truncating and pathogenic missense variants in ATP9A were significantly associated with schizophrenia ( p = 0.000372; odds Ratio = 5.48).
- Open Access
- 17 September 2026
- Published by Springer Nature in Genome Medicine
Genome sequencing improves diagnostic outcomes over panel and exome sequencings in myopathies: findings from the French PFMG2025 initiative
Background: Myopathies represent a very heterogeneous group of disease with multiple underlying causes, challenging for molecular genetic diagnosis. Hence, the diagnostic yield is very variable within the different myopathy subtypes. Current diagnostic strategies mainly rely on gene-panel or exome sequencing (ES) approaches, but they remain limited by the lack of analysis of deep intronic regions. In this study, we evaluated the diagnostic performance of a Genome Sequencing (GS) strategy for cases that were previously unresolved by gene-panel or ES in the context of myopathy diagnosis, as part of a large national scale GS strategy piloted by the French Genomic Medicine Initiative (PFMG2025). Methods: Two hundred and sixty-five patients with genetically undiagnosed myopathy who underwent GS analysis as part of the PFMG2025 from July 2020 to October 2024 were included in this retrospective study. Clinical, paraclinical and genetics data were collected from the two clinical GS laboratories SeqOIA (Paris, France) and AURAGEN (Lyon, France). Results: The diagnostic yield of GS in this study was of 26%, corresponding to a conclusive molecular diagnosis identifying likely pathogenic (ACMG class 4) or pathogenic (ACMG class 5) variants for 68/265 families. When considering candidate variants of unknown significance (VUS) that raised a strong diagnostic hypothesis, the diagnostic yield increased to 44%. GS was necessary for the resolution of 20.5% of cases with conclusive or candidate findings, as the variant should not have been detected using other techniques. Conclusions: This nationwide program for the molecular diagnosis of myopathy showed GS as a valuable and feasible approach allowing the elucidation of complex variants and the discovery of new pathogenic mechanisms. These results highlight the complex nature of neuromuscular genetic disorders and show how GS can help providing a genetic diagnosis for these conditions in a clinical practice.
- 17 September 2026
- Published by Springer Nature in Genome Medicine
Open AccessGenome sequencing improves diagnostic outcomes over panel and exome sequencings in myopathies: findings from the French PFMG2025 initiative
Background: Myopathies represent a very heterogeneous group of disease with multiple underlying causes, challenging for molecular genetic diagnosis. Hence, the diagnostic yield is very variable within the different myopathy subtypes. Current diagnostic strategies mainly rely on gene-panel or exome sequencing (ES) approaches, but they remain limited by the lack of analysis of deep intronic regions. In this study, we evaluated the diagnostic performance of a Genome Sequencing (GS) strategy for cases that were previously unresolved by gene-panel or ES in the context of myopathy diagnosis, as part of a large national scale GS strategy piloted by the French Genomic Medicine Initiative (PFMG2025). Methods: Two hundred and sixty-five patients with genetically undiagnosed myopathy who underwent GS analysis as part of the PFMG2025 from July 2020 to October 2024 were included in this retrospective study. Clinical, paraclinical and genetics data were collected from the two clinical GS laboratories SeqOIA (Paris, France) and AURAGEN (Lyon, France). Results: The diagnostic yield of GS in this study was of 26%, corresponding to a conclusive molecular diagnosis identifying likely pathogenic (ACMG class 4) or pathogenic (ACMG class 5) variants for 68/265 families. When considering candidate variants of unknown significance (VUS) that raised a strong diagnostic hypothesis, the diagnostic yield increased to 44%. GS was necessary for the resolution of 20.5% of cases with conclusive or candidate findings, as the variant should not have been detected using other techniques. Conclusions: This nationwide program for the molecular diagnosis of myopathy showed GS as a valuable and feasible approach allowing the elucidation of complex variants and the discovery of new pathogenic mechanisms. These results highlight the complex nature of neuromuscular genetic disorders and show how GS can help providing a genetic diagnosis for these conditions in a clinical practice.
- Open Access
- 12 May 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16
Fragmentomics features of cell free DNA in eating disorders
Eating disorders are lacking reliable biomarkers despite their severe psychiatric and medical burden. In this study, we examined plasma cell-free DNA (cfDNA) from patients with the restrictive (ANR), or binge-purge (ANBP) subtypes of anorexia nervosa, as well as from those with bulimia nervosa (BN), and controls, using the BIABooster electrophoresis method and shallow whole-genome sequencing to characterize cfDNA fragmentomics. While absolute cfDNA concentrations did not differ between groups, patients exhibited consistent qualitative alterations. Patients with BN showed increased cfDNA at the first nucleosomal peak, while all patient groups displayed shifts towards shorter fragments in the second and third nucleosomal peaks. End-motif analysis revealed higher motif diversity and trinucleotide sequence motifs TNN-type enrichment in ANR, together with a lower ratio of trinucleotide sequence motifs CGN to NCG, which has been correlated with hypomethylation. Multivariate analyses demonstrated that ANBP exhibits a distinct molecular profile that is not explained by combined effects of anorexia and bulimia. These findings suggest that cfDNA in eating disorders carries biologically meaningful signatures related to chromatin organization, nuclease activity, and methylation. This supports the potential of cfDNA as a minimally invasive biomarker for the clinical management of eating disorders.
- 12 May 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16
Open AccessFragmentomics features of cell free DNA in eating disorders
Eating disorders are lacking reliable biomarkers despite their severe psychiatric and medical burden. In this study, we examined plasma cell-free DNA (cfDNA) from patients with the restrictive (ANR), or binge-purge (ANBP) subtypes of anorexia nervosa, as well as from those with bulimia nervosa (BN), and controls, using the BIABooster electrophoresis method and shallow whole-genome sequencing to characterize cfDNA fragmentomics. While absolute cfDNA concentrations did not differ between groups, patients exhibited consistent qualitative alterations. Patients with BN showed increased cfDNA at the first nucleosomal peak, while all patient groups displayed shifts towards shorter fragments in the second and third nucleosomal peaks. End-motif analysis revealed higher motif diversity and trinucleotide sequence motifs TNN-type enrichment in ANR, together with a lower ratio of trinucleotide sequence motifs CGN to NCG, which has been correlated with hypomethylation. Multivariate analyses demonstrated that ANBP exhibits a distinct molecular profile that is not explained by combined effects of anorexia and bulimia. These findings suggest that cfDNA in eating disorders carries biologically meaningful signatures related to chromatin organization, nuclease activity, and methylation. This supports the potential of cfDNA as a minimally invasive biomarker for the clinical management of eating disorders.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification de marqueurs génétiques et épigénétiques de suivi des patient.es atteint.es de troubles du comportement alimentaire
Les troubles du comportement alimentaire (TCA) et particulièrement l'anorexie mentale (anorexia nervosa, AN) présentent un fort taux de rechute (>50%), une des mortalités les plus élevées de tous les troubles psychiatriques et de nombreuses comorbidités et représentent des challenges dans la prise en charge des patient.es. Il n'existe à ce jour aucun traitement pharmacologique pour la prise en charge thérapeutique des TCA. De plus, en dehors de la restauration pondérale, il n'existe à ce jour aucun marqueur biologique de la rémission alors même que les rechutes sont fréquentes et souvent précoces et la mortalité, la plus élevée parmi tous les troubles psychiatriques. Identifier de tels marqueurs peut être considéré comme une priorité des recherches portant sur les TCA. L'ensemble des travaux de cette thèse devrait permettre d'identifier des biomarqueurs permettant un meilleur suivi des patient.es. Les objectifs étant l'identification de biomarqueurs de rémission :avec l'identification de biomarqueurs d'expression géniques de comorbidité suicidaire et l'exploration de la physiopathologie de l'ADN libre circulant (ADNlc), mais également l'identification de biomarqueurs d'expression génique de rémission. Nous avons réalisé le RNA sequencing de 15 patientes atteintes de TCA présentant ou non des antécédents de tentative de suicide. Nous avons identifié plusieurs gènes dérégulés précédemment associés aux troubles de l'humeur, aux troubles dépressifs et au suicide. Nous avons observé un enrichissement dans les voies de l'immunité, de la dégranulation des neutrophiles, du TGFβ et du rythme circadien en rapport avec les comportements suicidaires dans l'AN. Après correction des tests multiples, nous avons identifié plusieurs gènes dysrégulés, tels que SNORD3C, précédemment impliqués dans le métabolisme de la vitamine D. Ce résultat a été confirmé dans une cohorte indépendante de 34 patientes atteintes d'AN. Les résultats de cette étude peuvent contribuer à une meilleure compréhension de la pathogenèse du comportement suicidaire dans l'AN et fournir des biomarqueurs potentiels, tels que SNORD3C, pour prédire le comportement suicidaire. Les concepts de biopsies liquides sont basés sur l'analyse de l'ADNlc dans le plasma et offrent des informations diagnostiques qui peuvent être, ou non, accessibles de manière conventionnelle par des biopsies invasives. L'analyse quantitative de ce type de marqueur a été réalisée sur l'ADN d'origine nucléaire et mitochondriale sur une cohorte de 98 patientes présentant divers TCA en comparaison à une cohorte contrôle. Il n'y a pas de différences franches en terme quantitatif entre les patientes et les contrôles. En revanche, nous avons montré que le profil de fragmentation des patient·es atteint·es de TCA diffère de celui des contrôles, suggérant l'implication des empreintes de nucléosomes, mettant potentiellement en évidence une contribution tissulaire différente au pool d'ADNlc. Ceci suggère l'importance de l'exploration qualitative exhaustive de l'ADNlc (taille, motifs terminaux, méthylation) et plus spécifiquement une étude ciblée des fragments issus du cerveau. La compréhension de la biologie de l'ADNlc et des données transcriptomiques chez les patient·es atteint·es de TCA permettra de mieux comprendre la physiopathologie, d'établir des biomarqueurs fiables de pronostic, et pourrait conduire à l'identification de nouvelles cibles thérapeutiques.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Identification de marqueurs génétiques et épigénétiques de suivi des patient.es atteint.es de troubles du comportement alimentaire
Les troubles du comportement alimentaire (TCA) et particulièrement l'anorexie mentale (anorexia nervosa, AN) présentent un fort taux de rechute (>50%), une des mortalités les plus élevées de tous les troubles psychiatriques et de nombreuses comorbidités et représentent des challenges dans la prise en charge des patient.es. Il n'existe à ce jour aucun traitement pharmacologique pour la prise en charge thérapeutique des TCA. De plus, en dehors de la restauration pondérale, il n'existe à ce jour aucun marqueur biologique de la rémission alors même que les rechutes sont fréquentes et souvent précoces et la mortalité, la plus élevée parmi tous les troubles psychiatriques. Identifier de tels marqueurs peut être considéré comme une priorité des recherches portant sur les TCA. L'ensemble des travaux de cette thèse devrait permettre d'identifier des biomarqueurs permettant un meilleur suivi des patient.es. Les objectifs étant l'identification de biomarqueurs de rémission :avec l'identification de biomarqueurs d'expression géniques de comorbidité suicidaire et l'exploration de la physiopathologie de l'ADN libre circulant (ADNlc), mais également l'identification de biomarqueurs d'expression génique de rémission. Nous avons réalisé le RNA sequencing de 15 patientes atteintes de TCA présentant ou non des antécédents de tentative de suicide. Nous avons identifié plusieurs gènes dérégulés précédemment associés aux troubles de l'humeur, aux troubles dépressifs et au suicide. Nous avons observé un enrichissement dans les voies de l'immunité, de la dégranulation des neutrophiles, du TGFβ et du rythme circadien en rapport avec les comportements suicidaires dans l'AN. Après correction des tests multiples, nous avons identifié plusieurs gènes dysrégulés, tels que SNORD3C, précédemment impliqués dans le métabolisme de la vitamine D. Ce résultat a été confirmé dans une cohorte indépendante de 34 patientes atteintes d'AN. Les résultats de cette étude peuvent contribuer à une meilleure compréhension de la pathogenèse du comportement suicidaire dans l'AN et fournir des biomarqueurs potentiels, tels que SNORD3C, pour prédire le comportement suicidaire. Les concepts de biopsies liquides sont basés sur l'analyse de l'ADNlc dans le plasma et offrent des informations diagnostiques qui peuvent être, ou non, accessibles de manière conventionnelle par des biopsies invasives. L'analyse quantitative de ce type de marqueur a été réalisée sur l'ADN d'origine nucléaire et mitochondriale sur une cohorte de 98 patientes présentant divers TCA en comparaison à une cohorte contrôle. Il n'y a pas de différences franches en terme quantitatif entre les patientes et les contrôles. En revanche, nous avons montré que le profil de fragmentation des patient·es atteint·es de TCA diffère de celui des contrôles, suggérant l'implication des empreintes de nucléosomes, mettant potentiellement en évidence une contribution tissulaire différente au pool d'ADNlc. Ceci suggère l'importance de l'exploration qualitative exhaustive de l'ADNlc (taille, motifs terminaux, méthylation) et plus spécifiquement une étude ciblée des fragments issus du cerveau. La compréhension de la biologie de l'ADNlc et des données transcriptomiques chez les patient·es atteint·es de TCA permettra de mieux comprendre la physiopathologie, d'établir des biomarqueurs fiables de pronostic, et pourrait conduire à l'identification de nouvelles cibles thérapeutiques.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Autosomal Dominant Missense DAG1 Variant Linked to Mild–Moderate LGMD R16
Limb‐girdle muscular dystrophies (LGMDs) are disorders with an important clinical heterogeneity, usually involving proximal limb muscles. One subtype, LGMD R16 (LGMD 2P), is an autosomal recessive condition caused by pathogenic variants in DAG1 , with clinical presentations ranging from mild to extremely severe forms. DAG1 is responsible for producing dystroglycan, an essential complex in the muscular protein network. Following translation, dystroglycan is cleaved into alpha‐dystroglycan, which undergoes glycosylation and acts as a sarcolemmal receptor for extracellular proteins, and beta‐dystroglycan, which connects to dystrophin. In recent years, heterozygous nonsense or frameshift DAG1 variants have been linked with asymptomatic hyperCKemia (increased serum creatine kinase levels) or mild muscular phenotypes characterized by fatigability and myalgia. Here, we describe a Romanian family comprising four affected individuals (one father and three sons) carrying the heterozygous missense DAG1 variant NM_004393.6:c.887G>A, NP_004384.5:p.(Gly296Asp) and showing a mild–moderate muscular phenotype similar to previous cases of DAG1 haploinsufficiency. Three of the affected individuals exhibit myopathic changes in muscle biopsies (increased fiber size variability, internalized nuclei, and regenerating fibers), while two demonstrate reduced alpha‐dystroglycan glycosylation in muscle tissue. Atomic force microscopy findings in myoblasts from one patient showed a significantly lower stiffness compared to controls. These findings align with prior reports and further support the pathogenicity of this variant.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Open AccessAutosomal Dominant Missense DAG1 Variant Linked to Mild–Moderate LGMD R16
Limb‐girdle muscular dystrophies (LGMDs) are disorders with an important clinical heterogeneity, usually involving proximal limb muscles. One subtype, LGMD R16 (LGMD 2P), is an autosomal recessive condition caused by pathogenic variants in DAG1 , with clinical presentations ranging from mild to extremely severe forms. DAG1 is responsible for producing dystroglycan, an essential complex in the muscular protein network. Following translation, dystroglycan is cleaved into alpha‐dystroglycan, which undergoes glycosylation and acts as a sarcolemmal receptor for extracellular proteins, and beta‐dystroglycan, which connects to dystrophin. In recent years, heterozygous nonsense or frameshift DAG1 variants have been linked with asymptomatic hyperCKemia (increased serum creatine kinase levels) or mild muscular phenotypes characterized by fatigability and myalgia. Here, we describe a Romanian family comprising four affected individuals (one father and three sons) carrying the heterozygous missense DAG1 variant NM_004393.6:c.887G>A, NP_004384.5:p.(Gly296Asp) and showing a mild–moderate muscular phenotype similar to previous cases of DAG1 haploinsufficiency. Three of the affected individuals exhibit myopathic changes in muscle biopsies (increased fiber size variability, internalized nuclei, and regenerating fibers), while two demonstrate reduced alpha‐dystroglycan glycosylation in muscle tissue. Atomic force microscopy findings in myoblasts from one patient showed a significantly lower stiffness compared to controls. These findings align with prior reports and further support the pathogenicity of this variant.
- Open Access
- 13 August 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (11) , 1433-1441
The Value of Enhancing Sonographic Phenotyping to Improve the Diagnostic Yield of Noninvasive Prenatal Diagnosis (NIPD) for Achondroplasia
Objectives: Achondroplasia is the most common form of skeletal dysplasia and is usually suspected in the third trimester of pregnancy based on abnormal sonographic findings. Non‐invasive prenatal diagnosis (NIPD), based on the detection of pathogenic FGFR3 variants in maternal plasma, provides an accurate genetic confirmation. The aim of this study was to identify the sonographic markers most strongly associated with achondroplasia, with the intention of enhancing the specificity of NIPD referrals and improving diagnostic efficiency, thereby supporting clinicians in their diagnostic approach. Methods: A retrospective cohort study was conducted on 275 NIPD tests performed in the laboratory between 2017 and 2023. Of these, 176 were requested due to sonographic abnormalities suggestive of achondroplasia. Sonographic reports were systematically reviewed to identify key ultrasound features correlated with a positive NIPD result. Results: Among the NIPD tests ordered due to sonographic anomalies, 34.1% were confirmed positive for achondroplasia. Abnormal proximal end of the femur, frontal bossing, and a pronounced nasal saddle were the most specific markers, achieving a diagnostic yield of 87.5% when all three features were present. In contrast, short femur length alone had a poor diagnostic yield (8.9%). Conclusion: Targeted sonographic phenotyping significantly improves the diagnostic yield of NIPD for achondroplasia. These findings support the need for more refined prenatal screening guidelines to enhance test specificity and optimise patient care as new achondroplasia treatments emerge.
- 13 August 2025
- Published by Wiley in Prenatal Diagnosis
- Vol. 45 (11) , 1433-1441
Open AccessThe Value of Enhancing Sonographic Phenotyping to Improve the Diagnostic Yield of Noninvasive Prenatal Diagnosis (NIPD) for Achondroplasia
Objectives: Achondroplasia is the most common form of skeletal dysplasia and is usually suspected in the third trimester of pregnancy based on abnormal sonographic findings. Non‐invasive prenatal diagnosis (NIPD), based on the detection of pathogenic FGFR3 variants in maternal plasma, provides an accurate genetic confirmation. The aim of this study was to identify the sonographic markers most strongly associated with achondroplasia, with the intention of enhancing the specificity of NIPD referrals and improving diagnostic efficiency, thereby supporting clinicians in their diagnostic approach. Methods: A retrospective cohort study was conducted on 275 NIPD tests performed in the laboratory between 2017 and 2023. Of these, 176 were requested due to sonographic abnormalities suggestive of achondroplasia. Sonographic reports were systematically reviewed to identify key ultrasound features correlated with a positive NIPD result. Results: Among the NIPD tests ordered due to sonographic anomalies, 34.1% were confirmed positive for achondroplasia. Abnormal proximal end of the femur, frontal bossing, and a pronounced nasal saddle were the most specific markers, achieving a diagnostic yield of 87.5% when all three features were present. In contrast, short femur length alone had a poor diagnostic yield (8.9%). Conclusion: Targeted sonographic phenotyping significantly improves the diagnostic yield of NIPD for achondroplasia. These findings support the need for more refined prenatal screening guidelines to enhance test specificity and optimise patient care as new achondroplasia treatments emerge.
- Open Access
Comparison of long-read sequencing strategies for resolving complex genotypes at Facioscapulohumeral dystrophy-associated loci
Background Facioscapulohumeral dystrophy (FSHD) is typically caused by contraction of the D4Z4 repeat array at chromosome 4q35 (FSHD1) or pathogenic variants in the SMCHD1 gene (FSHD2). While these account for the majority of cases, 1–2% of patients present with clinical features of FSHD but lack a known genetic cause, revealing a diagnostic gap. In Previous studies, we identified over 70 patients with structural rearrangements involving the 4q35 or 10q26 loci, some of which may be pathogenic in the absence of other FSHD-associated features. Methods Given their diagnostic relevance, we performed detailed structural analyses of these rearrangements using high-resolution long-read sequencing technologies (Oxford Nanopore and PacBio) for seven patients carrying different structural variants of the 4q35 or 10q26 loci. Results These approaches enabled us to resolve nucleotide-level architecture and methylation patterns across the 4q35 and 10q26 loci. We show that duplicated alleles arise from intrachromosomal recombination between LSau and β-satellite elements, producing variable deletions within D4Z4, with breakpoints differing among patients. These complex structural variants are not detectable using standard technologies like Bionano Optical Genome Mapping and require manual curation for identification. Importantly, determining the pathogenic relevance of these rearrangements necessitates integrating structural and epigenetic features typically associated with FSHD. Conclusion The results highlight the importance of thorough molecular analysis for FSHD patients who test negative for FSHD1 and FSHD2, advocating for expanded diagnostic strategies. Comprehensive evaluation of 4q35 structural variants is essential for improving diagnosis accuracy, guiding genetic counseling, and optimizing care for patients with atypical FSHD presentations. Graphical Abstract Hypothetical model for the formation of 4q35 intrachromosomal duplications. We speculate that the breakpoint occurs in the proximal region of a D4Z4 units that corresponds to LSau repeats and involves the distal βsatellite array. The duplicated array is then inserted in the distal part of the locus mapped by the most telomeric red probe used for MC.
Open AccessComparison of long-read sequencing strategies for resolving complex genotypes at Facioscapulohumeral dystrophy-associated loci
Background Facioscapulohumeral dystrophy (FSHD) is typically caused by contraction of the D4Z4 repeat array at chromosome 4q35 (FSHD1) or pathogenic variants in the SMCHD1 gene (FSHD2). While these account for the majority of cases, 1–2% of patients present with clinical features of FSHD but lack a known genetic cause, revealing a diagnostic gap. In Previous studies, we identified over 70 patients with structural rearrangements involving the 4q35 or 10q26 loci, some of which may be pathogenic in the absence of other FSHD-associated features. Methods Given their diagnostic relevance, we performed detailed structural analyses of these rearrangements using high-resolution long-read sequencing technologies (Oxford Nanopore and PacBio) for seven patients carrying different structural variants of the 4q35 or 10q26 loci. Results These approaches enabled us to resolve nucleotide-level architecture and methylation patterns across the 4q35 and 10q26 loci. We show that duplicated alleles arise from intrachromosomal recombination between LSau and β-satellite elements, producing variable deletions within D4Z4, with breakpoints differing among patients. These complex structural variants are not detectable using standard technologies like Bionano Optical Genome Mapping and require manual curation for identification. Importantly, determining the pathogenic relevance of these rearrangements necessitates integrating structural and epigenetic features typically associated with FSHD. Conclusion The results highlight the importance of thorough molecular analysis for FSHD patients who test negative for FSHD1 and FSHD2, advocating for expanded diagnostic strategies. Comprehensive evaluation of 4q35 structural variants is essential for improving diagnosis accuracy, guiding genetic counseling, and optimizing care for patients with atypical FSHD presentations. Graphical Abstract Hypothetical model for the formation of 4q35 intrachromosomal duplications. We speculate that the breakpoint occurs in the proximal region of a D4Z4 units that corresponds to LSau repeats and involves the distal βsatellite array. The duplicated array is then inserted in the distal part of the locus mapped by the most telomeric red probe used for MC.
- Open Access
- 16 January 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 182, 358-367
SNORD3C, a blood biomarker associated to suicide attempts in patients with anorexia nervosa
- 16 January 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 182, 358-367
Open AccessSNORD3C, a blood biomarker associated to suicide attempts in patients with anorexia nervosa
- Open Access
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 9301465
Variants in CAPN3 Causing Autosomal Dominant Limb–Girdle Muscular Dystrophy Combined With Calpain‐3 Deficiency
Limb–girdle muscular dystrophy Type 2A/R1 or calpain‐3 deficiency is the most common autosomal recessive limb–girdle muscular dystrophy. However, in recent years, autosomal dominant cases and families with calpain‐3 deficiency have been reported, and there is an emerging interest in looking for single variants in the calpain‐3 gene in mildly to moderately affected patients with limb–girdle muscular dystrophy without biallelic gene variants in CAPN3. Here, we report four cases with creatine kinase levels above 1500 U/L, mild‐to‐moderate proximal weakness, waddling gait, and scapular winging. Two patients, a son and his father, are heterozygous for the CAPN3 variant c.304C>T; p.(Pro102Ser), which has previously been reported in patients with compound heterozygous variants in CAPN3. The third and fourth patients were heterozygous for c.1371C>G; p.(Asn457Lys) and c.1490C>T; p.Ala497_Glu508del, respectively, neither of which has been reported before. All four patients had a near‐complete loss of calpain‐3 as determined by western blotting. While inherited autosomal dominant calpainopathy has now been firmly established, additional single cases of dominant calpainopathy are likely to emerge; some will be associated with clinical findings from parents or siblings, while others will arise from spontaneous mutations, but nevertheless with similar clinical findings of mild‐to‐moderate proximal weakness, increased level of creatine kinase, and near‐complete loss of calpain‐3 protein in affected individuals. This report expands the known number of variants causing dominant calpainopathy from 8 to 11 that appears to exclusively reside in two out of four domains that make up calpain‐3. This information could aid in determining whether a CAPN3 variant of unknown significance is pathological.
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 9301465
Open AccessVariants in CAPN3 Causing Autosomal Dominant Limb–Girdle Muscular Dystrophy Combined With Calpain‐3 Deficiency
Limb–girdle muscular dystrophy Type 2A/R1 or calpain‐3 deficiency is the most common autosomal recessive limb–girdle muscular dystrophy. However, in recent years, autosomal dominant cases and families with calpain‐3 deficiency have been reported, and there is an emerging interest in looking for single variants in the calpain‐3 gene in mildly to moderately affected patients with limb–girdle muscular dystrophy without biallelic gene variants in CAPN3. Here, we report four cases with creatine kinase levels above 1500 U/L, mild‐to‐moderate proximal weakness, waddling gait, and scapular winging. Two patients, a son and his father, are heterozygous for the CAPN3 variant c.304C>T; p.(Pro102Ser), which has previously been reported in patients with compound heterozygous variants in CAPN3. The third and fourth patients were heterozygous for c.1371C>G; p.(Asn457Lys) and c.1490C>T; p.Ala497_Glu508del, respectively, neither of which has been reported before. All four patients had a near‐complete loss of calpain‐3 as determined by western blotting. While inherited autosomal dominant calpainopathy has now been firmly established, additional single cases of dominant calpainopathy are likely to emerge; some will be associated with clinical findings from parents or siblings, while others will arise from spontaneous mutations, but nevertheless with similar clinical findings of mild‐to‐moderate proximal weakness, increased level of creatine kinase, and near‐complete loss of calpain‐3 protein in affected individuals. This report expands the known number of variants causing dominant calpainopathy from 8 to 11 that appears to exclusively reside in two out of four domains that make up calpain‐3. This information could aid in determining whether a CAPN3 variant of unknown significance is pathological.
- 26 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (6) , 784-792
SMCHD1 genetic variants in type 2 facioscapulohumeral dystrophy and challenges in predicting pathogenicity and disease penetrance
The molecular diagnosis of type 1 facioscapulohumeral muscular dystrophy (FSHD1) relies on the detection of a shortened D4Z4 array at the 4q35 locus. Until recently, the diagnosis of FSHD2 relied solely on the absence of a shortened D4Z4 allele in clinically affected patients. It is now established that most FSHD2 cases carry a heterozygous variant in the SMCHD1 gene. A decrease in D4Z4 DNA methylation is observed in both FSHD1 and FSHD2 patients. To refine the molecular diagnosis of FSHD2, we performed a molecular diagnosis of SMCHD1 in 54 patients with a clinical diagnosis of FSHD. All patients carry a D4Z4 array of more than 10 D4Z4 units, or a cis-duplication of the locus. Forty-eight of them carry a variant in SMCHD1 and six other cases are hemizygous for the 18p32 locus encompassing SMCHD1. Genetic and epigenetic analyses were considered to assess the pathogenicity of new SMCHD1 variants and of variants previously classified as likely pathogenic. In comparison to the healthy population and FSHD1 patients, we defined a threshold of 40% of methylation at the D4Z4 DR1 site as associated with SMCHD1 variants or SMCHD1 hemizygosity. We also showed that the number of D4Z4 on the shortest 4q allele ranges from 11 up to 35 units in these same patients. Using variant interpretation and protein structure prediction tools, we also highlight the difficulty in interpreting the impact of pathogenic variants on SMCHD1 function. Our study further emphasizes the intriguing relationship between D4Z4 methylation, SMCHD1 variants with SMCHD1 protein structure-function in FSHD.
- 26 December 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (6) , 784-792
SMCHD1 genetic variants in type 2 facioscapulohumeral dystrophy and challenges in predicting pathogenicity and disease penetrance
The molecular diagnosis of type 1 facioscapulohumeral muscular dystrophy (FSHD1) relies on the detection of a shortened D4Z4 array at the 4q35 locus. Until recently, the diagnosis of FSHD2 relied solely on the absence of a shortened D4Z4 allele in clinically affected patients. It is now established that most FSHD2 cases carry a heterozygous variant in the SMCHD1 gene. A decrease in D4Z4 DNA methylation is observed in both FSHD1 and FSHD2 patients. To refine the molecular diagnosis of FSHD2, we performed a molecular diagnosis of SMCHD1 in 54 patients with a clinical diagnosis of FSHD. All patients carry a D4Z4 array of more than 10 D4Z4 units, or a cis-duplication of the locus. Forty-eight of them carry a variant in SMCHD1 and six other cases are hemizygous for the 18p32 locus encompassing SMCHD1. Genetic and epigenetic analyses were considered to assess the pathogenicity of new SMCHD1 variants and of variants previously classified as likely pathogenic. In comparison to the healthy population and FSHD1 patients, we defined a threshold of 40% of methylation at the D4Z4 DR1 site as associated with SMCHD1 variants or SMCHD1 hemizygosity. We also showed that the number of D4Z4 on the shortest 4q allele ranges from 11 up to 35 units in these same patients. Using variant interpretation and protein structure prediction tools, we also highlight the difficulty in interpreting the impact of pathogenic variants on SMCHD1 function. Our study further emphasizes the intriguing relationship between D4Z4 methylation, SMCHD1 variants with SMCHD1 protein structure-function in FSHD.